John M. Pritchard
Glasgow, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic αvβ6 Integrin Inhibitors.
Journal: Journal of medicinal chemistry
Published: September 13, 2024
TGM6, a helminth secretory product, mimics TGF-β binding to TβRII to antagonize TGF-β signaling in fibroblasts.
Journal: bioRxiv : the preprint server for biology
Published: January 08, 2024
Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease.
Journal: Nature communications
Published: October 24, 2022
Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis.
Journal: Journal of medicinal chemistry
Published: September 10, 2019
Profile of a Highly Selective Quaternized Pyrrolidine Betaine αvβ6 Integrin Inhibitor-(3S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((1S and 1R,3R)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective Methylation.
Journal: Journal of medicinal chemistry
Published: August 06, 2019
Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αvβ6 Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis.
Journal: Journal of medicinal chemistry
Published: September 15, 2018
Synthesis and determination of absolute configuration of a non-peptidic αvβ6 integrin antagonist for the treatment of idiopathic pulmonary fibrosis.
Journal: Organic & biomolecular chemistry
Published: May 27, 2016
4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy.
Journal: Bioorganic & medicinal chemistry letters
Published: May 11, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026